Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Prarthana Parthasarathy"'
Publikováno v:
Journal of Scientific Innovation in Medicine, Vol 2, Iss 2 (2019)
Externí odkaz:
https://doaj.org/article/e755f1e959f04e2da1f622d166d52f53
Autor:
Silvia Ferrari, Neal Shiv Chawla, Michela Pierini, Imran S. Syed, William E. Mendanha, Emanuela Marchesi, Anna Paioli, Kumar Sankhala, Madhuri Sudan, M. Piccinni Leopardi, Prarthana Parthasarathy, Sant P. Chawla, Emanuela Palmerini, P. Picci
Publikováno v:
European Journal of Cancer. 76:118-124
Background Giant-cell tumours of bone (GCTB) are RANK/RANK-ligand (RANKL) positive, aggressive and progressive osteolytic tumours. Denosumab, a RANKL inhibitor, was FDA-approved for adults and skeletally mature adolescents with unresectable GCTB or w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24eff198fbe263c96faf179303ba4e51
https://doi.org/10.1016/j.ejca.2017.01.028
https://doi.org/10.1016/j.ejca.2017.01.028
Autor:
Imran S. Syed, Prarthana Parthasarathy, Anna Paioli, Piero Picci, Neal Shiv Chawla, Justin Daneshrad, Sant P. Chawla, William E. Mendanha, Emanuela Palmerini, Stefano Ferrari, Emanuela Marchesi, Kamalesh Kumar Sankhala, Madhuri Sudan, Martina Piccinni Leopardi
Publikováno v:
Alma Mater Studiorum Università di Bologna-IRIS
11021Background: Giant cell tumours of bone (GCTB’s) are RANK-ligand (RANK-L) positive, aggressive and progressive osteolytic tumors. Denosumab, a RANK-L inhibitor, was FDA-approved for adults and ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985ad0262ebc5db9b435c7154ac310dc
https://doi.org/10.1200/jco.2016.34.15_suppl.11021
https://doi.org/10.1200/jco.2016.34.15_suppl.11021
Autor:
Babak Aryanfar, Sant P. Chawla, Katherine K. Kim, William W. Tseng, Susan Arasheben, Prarthana Parthasarathy, William E. Mendanha, Neal Shiv Chawla, Bryan Leong, Imran S. Syed, Kamalesh Kumar Sankhala, Madhuri Sudan, Erlinda M. Gordon, Rishi Nanda, Justin Daneshrad
Publikováno v:
Journal of Clinical Oncology. 34:11052-11052
11052Background: Trabectedin (T) is an anti-tumor agent used in the treatment of advanced soft-tissue sarcomas (STS). It interferes with DNA replication, causing double strand breaks and apoptosis,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a473e64d10752f14a1d530b9810b2ae0
https://doi.org/10.1200/jco.2016.34.15_suppl.11052
https://doi.org/10.1200/jco.2016.34.15_suppl.11052